ContributorsPublishersAdvertisers

Sintilimab Combo Reduces Risk of Progression by 54% in EGFR-Mutated Nonsquamous NSCLC

onclive.com
 2021-11-22

The addition of sintilimab to a bevacizumab biosimilar and pemetrexed/cisplatin resulted in a statistically significant and clinically meaningful improvement in progression-free survival vs chemotherapy alone in patients with EGFR-mutated, nonsquamous non–small cell lung cancer who progressed after an EGFR TKI. The addition of sintilimab (Tyvyt) to a bevacizumab biosimilar...

www.onclive.com

Comments / 0

Comments / 0